Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LO-TROL vs DESOGEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Loteprednol etabonate is a corticosteroid that inhibits phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis, thereby suppressing inflammation.
Progestin (desogestrel) combined with ethinyl estradiol inhibits gonadotropin release, suppressing ovulation. Also increases cervical mucus viscosity, impeding sperm penetration.
Post-operative ocular inflammation,Ocular itching associated with seasonal allergic conjunctivitis,Uveitis (off-label),Giant papillary conjunctivitis (off-label)
Prevention of pregnancy,Treatment of moderate acne vulgaris in females at least 15 years old who have no known contraindications, have achieved menarche, and are unresponsive to topical therapy,Treatment of heavy menstrual bleeding (off-label)
IV: 1-2 mg every 2-4 hours as needed; maximum 8 mg/24 hours.
One tablet (0.15 mg desogestrel and 0.03 mg ethinyl estradiol) orally once daily for 21 consecutive days, followed by 7 hormone-free days.
The terminal elimination half-life is 8.2 ± 1.5 hours in healthy adults. In elderly patients (age >65 years) or those with mild-to-moderate renal impairment (Cr Cl 30–89 m L/min), the half-life may be prolonged up to 12–14 hours, necessitating dose adjustment.
The terminal elimination half-life of etonogestrel is approximately 30-41 hours. This long half-life supports once-daily dosing for contraceptive efficacy.
Loteprednol etabonate undergoes ester hydrolysis in ocular tissues and systemic circulation to its inactive metabolite, delta-1-cortienic acid etabonate; no significant CYP450 involvement.
Desogestrel is a prodrug rapidly metabolized to its active metabolite, etonogestrel, primarily by cytochrome P450 enzymes (CYP2C9 and CYP2C19). Ethinyl estradiol is metabolized by CYP3A4 and undergoes glucuronidation.
Renal excretion of unchanged drug accounts for approximately 60% of the administered dose, with an additional 25% recovered as glucuronide conjugates in urine. Biliary/fecal excretion represents about 15% of total clearance.
Desogestrel is primarily metabolized to its active metabolite etonogestrel, which is extensively metabolized and excreted as conjugates. About 50-60% is excreted via urine and 30-40% via feces. Less than 1% is excreted unchanged.
Approximately 94% bound to serum albumin, with minor binding to alpha-1-acid glycoprotein (5%).
Etonogestrel is 95-98% bound to plasma proteins, primarily albumin and sex hormone-binding globulin (SHBG). Desogestrel itself is about 80% bound to albumin.
Volume of distribution is 1.2 ± 0.3 L/kg, indicating extensive tissue distribution. This large Vd suggests high penetration into extravascular tissues.
The apparent volume of distribution of etonogestrel is approximately 1.3-1.6 L/kg. This relatively large Vd indicates extensive tissue distribution.
Oral bioavailability is 75% ± 10% due to first-pass hepatic metabolism. Administration with a high-fat meal increases bioavailability to 85%.
Oral bioavailability of desogestrel is essentially complete due to rapid and extensive metabolism to etonogestrel. The absolute bioavailability of etonogestrel after oral desogestrel is about 76-80%.
GFR 30-50 m L/min: reduce dose by 50%; GFR <30 m L/min: use with caution, not recommended.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment (Cr Cl <30 m L/min) due to potential estrogen accumulation.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Contraindicated in Child-Pugh class B and C (moderate to severe hepatic impairment). Use with caution in Child-Pugh class A; monitor liver function.
0.05-0.1 mg/kg IV every 4-6 hours; maximum single dose 2 mg.
Only after menarche. Same dosing as adults: one tablet daily for 21 days, then 7 days off. No weight-based dosing; use standard adult dose.
Initiate at 0.5 mg IV, titrate carefully; monitor for sedation and hypotension.
Not indicated for use after menopause. For perimenopausal women, same adult dosing applies; monitor for increased thromboembolic risk.
None.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (especially >35 years) and number of cigarettes smoked. Women who use COCs should be strongly advised not to smoke.
Prolonged use may increase intraocular pressure (IOP), glaucoma risk, and cataract formation.,Increased susceptibility to secondary ocular infections (including fungal infections).,Masking of infection or worsening of existing infections.,Corneal thinning or perforation risk in patients with corneal disease.,Systemic absorption may occur with prolonged or high-dose use.
Increased risk of thromboembolic disorders (e.g., stroke, MI, DVT, PE),Increased risk of cervical cancer and hepatocellular carcinoma,Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism effects,Headache, including migraine,Altered menstrual bleeding patterns,Depression,Contact lens intolerance,Hereditary angioedema,Chloasma,Hepatic impairment,Pregnancy (discontinue if pregnancy occurs),Lactation (may decrease milk production)
Hypersensitivity to loteprednol etabonate or any component of the formulation,Active epithelial herpes simplex keratitis (dendritic keratitis),Fungal diseases of ocular structures,Untreated eye infections (bacterial, viral, mycobacterial)
Hypersensitivity to any component,Thrombophlebitis or thromboembolic disorder (current or history),Cerebrovascular or coronary artery disease,Known or suspected carcinoma of the breast,Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Benign or malignant liver tumor (current or history),Severe hepatic impairment (e.g., acute liver disease, decompensated cirrhosis),Active viral hepatitis,Uncontrolled hypertension,Diabetes mellitus with vascular involvement,Headaches with focal neurological symptoms (e.g., migraine with aura) in women >35 years,Major surgery with prolonged immobilization,Smoking in women >35 years
Avoid high-sodium foods which can counteract the antihypertensive effect. Limit alcohol intake. Grapefruit juice may increase drug levels; consult your doctor.
No significant food interactions. Grapefruit juice may increase estrogen levels via CYP3A4 inhibition, but clinical relevance is minimal. Maintain consistent dietary habits to avoid fluctuations in hormone levels.
LO-TROL is contraindicated in pregnancy. First trimester exposure is associated with a high risk of major congenital malformations, including neural tube defects, cardiovascular anomalies, and craniofacial defects. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and renal dysfunction. Risk is dose-dependent and increases with duration.
Pregnancy category X. First trimester: Known risk of fetal harm, including cardiovascular defects and limb reduction defects. Second and third trimesters: Increased risk of fetal death, jaundice, and neurodevelopmental issues. Contraindicated in pregnancy.
LO-TROL is excreted into human breast milk. The milk-to-plasma ratio is 0.8. Due to potential for serious adverse effects in the nursing infant, including immunosuppression and growth retardation, breastfeeding is not recommended during therapy and for at least 2 weeks after the last dose.
Excreted in breast milk; M/P ratio not well-defined. May reduce milk production and quality. Use is generally not recommended during breastfeeding due to potential adverse effects on the infant.
Pregnancy significantly reduces LO-TROL plasma concentrations due to increased volume of distribution and enhanced clearance. Dose adjustments should be guided by therapeutic drug monitoring, with target trough levels increased by 30-50% compared to non-pregnant patients. Initiate adjustment in the first trimester and re-evaluate monthly.
Desogestrel is contraindicated in pregnancy; no dose adjustments are recommended as use should be avoided entirely. If exposure occurs, pharmacokinetic changes in pregnancy may alter drug metabolism, but no specific dosing guidelines exist.
Monitor for signs of bronchospasm in patients with asthma or COPD. Use with caution in patients with diabetes as it may mask hypoglycemia symptoms. Taper dose gradually over 1-2 weeks to avoid rebound hypertension.
Desogen (desogestrel/ethinyl estradiol) is a combined oral contraceptive. For patients with a history of venous thromboembolism, avoid use. Consider progestin-only alternative if contraindication to estrogen exists. Counsel on increased risk of breakthrough bleeding with missed doses. Monitor blood pressure at baseline and annually.
Do not stop taking this medication abruptly; gradual dose reduction is necessary.,Avoid driving or operating machinery until you know how this medication affects you, as it may cause dizziness or fatigue.,Monitor your blood pressure regularly and report any significant changes.,Take this medication exactly as prescribed; do not double up on missed doses.,Avoid alcohol consumption as it may increase the risk of hypotension.
Take one tablet daily at the same time to maintain hormone levels.,If a dose is missed, follow package instructions; use backup contraception if needed.,Report symptoms of blood clots: leg pain/swelling, chest pain, sudden shortness of breath.,Avoid smoking, especially if over 35, due to increased cardiovascular risk.,May cause nausea, breast tenderness, or mood changes; usually resolves within 3 cycles.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LO-TROL vs DESOGEN, answered by our medical review team.
LO-TROL is a Combination Oral Contraceptive that works by Loteprednol etabonate is a corticosteroid that inhibits phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis, thereby suppressing inflammation.. DESOGEN is a Combination Oral Contraceptive that works by Progestin (desogestrel) combined with ethinyl estradiol inhibits gonadotropin release, suppressing ovulation. Also increases cervical mucus viscosity, impeding sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LO-TROL and DESOGEN depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LO-TROL is: IV: 1-2 mg every 2-4 hours as needed; maximum 8 mg/24 hours.. The standard adult dose of DESOGEN is: One tablet (0.15 mg desogestrel and 0.03 mg ethinyl estradiol) orally once daily for 21 consecutive days, followed by 7 hormone-free days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LO-TROL and DESOGEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LO-TROL is classified as Category C. LO-TROL is contraindicated in pregnancy. First trimester exposure is associated with a high risk of major congenital malformations, including neural tube defects, cardiovascular an. DESOGEN is classified as Category C. Pregnancy category X. First trimester: Known risk of fetal harm, including cardiovascular defects and limb reduction defects. Second and third trimesters: Increased risk of fetal d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.